Advertisement

Psychopharmacology

, Volume 93, Issue 1, pp 72–76 | Cite as

Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity

  • R. M. Arendt
  • D. J. Greenblatt
  • D. C. Liebisch
  • M. D. Luu
  • S. M. Paul
Original Investigations

Abstract

Factors influencing brain uptake of benzodiazepine derivatives were evaluated in adult Sprague Dawley rats (n=8–10 per drug). Animals received single intraperitoneal doses of alprazolam, triazolam, lorazepam, flunitrazepam, diazepam, midazolam, desmethyldiazepam, or clobazam. Concentrations of each drug (and metabolites) in whole brain and serum 1 h after dosage were determined by gas chromatography. Serum free fraction was measured by equilibrium dialysis. In vitro binding affinity (apparentK i) of each compound was estimated based on displacement of tritiated flunitrazepam in washed membrane preparations from rat cerebral cortex. Lipid solubility of each benzodiazepine was estimated using the reverse-phase liquid chromatographic (HPLC) retention index at physiologic pH. There was no significant relation between brain:total serum concentration ratio and either HPLC retention (r=0.18) or bindingK i (r=−0.34). Correction of uptake ratios for free as opposed to total serum concentration yielded a highly significant correlation with HPLC retention (r=0.78,P<0.005). However, even the corrected ratio was not correlated with bindingK i (r=−0.22). Thus a benzodiazepine's capacity to diffuse from systemic blood into brain tissue is much more closely associated with the physico-chemical property of lipid solubility than with specific affinity. Unbound rather than total serum or plasma concentration most accurately reflects the quantity of drug available for diffusion.

Key words

Benzodiazepines Binding affinity Lipid solubility Brain uptake Metabolites Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy DR, Greenblatt DJ, Divoll M (1983) Prolonged accumulation of diazepam in obesity. J Clin Pharmacol 23:369–376PubMedGoogle Scholar
  2. Arendt RM, Greenblatt DJ, Jong RH, Bonin JD, Abernethy DR, Ehrenberg BL, Giles HG, Sellers EM, Shader RI (1983) In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action, and peripheral distribution. J Pharmacol Exp Ther 227:95–106Google Scholar
  3. Arendt RM, Greenblatt DJ, Garland WA (1984) Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma. Pharmacology 29:158–164PubMedGoogle Scholar
  4. Borea PA, Bonora A (1983) Brain receptor binding and lipophilic character of benzodiazepines. Biochem Pharmacol 32:603–607PubMedCrossRefGoogle Scholar
  5. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA (1977) Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481–494PubMedCrossRefGoogle Scholar
  6. Greenblatt DJ (1980) Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. J Pharm Sci 69:1351:1352PubMedGoogle Scholar
  7. Greenblatt DJ, Shader RI (1985) Clinical pharmacokinetics of the benzodiazepines. In: Smith DE, Wesson DR (eds) The benzodiazepines: current standards for medical practice. M.T.P. Press, Lancaster, UK, pp 43–58Google Scholar
  8. Greenblatt DJ, Franke K, Shader RI (1978) Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography: use in pharmacokinetic studies of lorazepam. J Chromatogr 146:311–320PubMedGoogle Scholar
  9. Greenblatt DJ, Ochs HR, Lloyd BL (1980) Entry of diazepam and its major metabolite into cerebrospinal fluid. Psychopharmacology 70:89–93PubMedCrossRefGoogle Scholar
  10. Greenblatt DJ, Laughren TP, Allen MD, Harmatz JS, Shader RI (1981a) Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol 11:35–40PubMedGoogle Scholar
  11. Greenblatt DJ, Divoll M, Moschitto LJ, Shader RI (1981b) Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr 225:202–207PubMedGoogle Scholar
  12. Greenblatt DJ, Shader RI, Abernethy DR, Ochs HR, Divoll M, Sellers EM (1982a) Benzodiazepines and the challenge of pharmacokinetic taxonomy. In: Usdin E, Skolnick P, Tallman JF, Greenblatt D, Paul SM (eds) Pharmacology of benzodiazepines. MacMillan, London, pp 257–269Google Scholar
  13. Greenblatt DJ, Sellers EM, Koch-Weser J (1982b) Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol 22:259–263PubMedGoogle Scholar
  14. Greenblatt DJ, Ochs HR, Locniskar A, Lauven PM (1982c) Automated electron-capture gas chromatographic analysis of flunitrazepam in plasma. Pharmacology 24:82–87PubMedGoogle Scholar
  15. Greenblatt DJ, Shader RI, Abernethy DR (1983a) Current status of benzodiazepines. N Engl J Med 309:354–358, 410–416PubMedCrossRefGoogle Scholar
  16. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI (1983b) Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 14:251–292PubMedGoogle Scholar
  17. Greenblatt DJ, Arendt RM, Abernethy DR, Giles HG, Sellers EM, Shader RI (1983c) In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth 55:985–989PubMedGoogle Scholar
  18. Greenblatt DJ, Divoll M, Shader RI (1983d) Automated gas chromatographic determination of plasma alprazolam concentrations. J Clin Psychopharmacol 3:366–368PubMedGoogle Scholar
  19. Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI (1983e) Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. Clin Pharmacokinet 8:83–94PubMedGoogle Scholar
  20. Greenblatt DJ, Abernethy DR, Morse DS, Shader RI, Harmatz JS (1984) Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 310:1639–1643PubMedCrossRefGoogle Scholar
  21. Guentert TW (1984) Pharmacokinetics of benzodiazepines and of their metabolites. Prog Drug Metab 8:241–386Google Scholar
  22. Klotz U, Kangas L, Kanto J (1980) Clinical pharmacokinetics of benzodiazepines. Prog Pharmacol 3 (No. 3):1–72Google Scholar
  23. McPherson GA (1983) A practical computer-based approach to the analysis of radioligand binding experiments. Comput Progr Biomed 17:107–114CrossRefGoogle Scholar
  24. Miller LG, Greenblatt DJ, Shader RI (1987a) Benzodiazepine receptor binding: influence of physiologic and pharmacologic factors. Biopharm Drug Dispos 8:103–114PubMedGoogle Scholar
  25. Miller LG, Greenblatt DJ, Paul SM, Shader RI (1987b) Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 240:516–522PubMedGoogle Scholar
  26. Moschitto LJ, Greenblatt DJ (1983) Concentration-independent plasma protein binding of benzodiazepines. J Pharm Pharmacol 35:179–180PubMedGoogle Scholar
  27. Müller WE (1981) The benzodiazepine receptor: an update. Pharmacology 22:153–161PubMedCrossRefGoogle Scholar
  28. Ochs HR, Greenblatt DJ, Eckardt B, Harmatz JS, Shader RI (1983) Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther 33:471–476PubMedCrossRefGoogle Scholar
  29. Ochs HR, Greenblatt DJ, Lüttkenhorst M, Verburg-Ochs B (1984) Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage. Eur J Clin Pharmacol 26:499–503PubMedCrossRefGoogle Scholar
  30. Reves JG, Fragen RH, Vinik HR, Greenblatt DJ (1985) Midazolam: pharmacology and uses. Anesthesiology 62:310–324PubMedGoogle Scholar
  31. Scavone JM, Friedman H, Greenblatt DJ, Shader RI (1987) Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arzneimittelforschung 37:2–6PubMedGoogle Scholar
  32. Sellers EM, Naranjo CA, Khouw V, Greenblatt DJ (1982) Binding of benzodiazepines to plasma proteins. In: Usdin E, Skolnick P, Tallman JF, Greenblatt D, Paul SM (eds) Pharmacology of benzodiazepines. MacMillan, London, pp 271–284Google Scholar
  33. Sieghart W, Eichinger A, Riederer P, Jellinger K (1985) Comparison of benzodiazepine receptor binding in membranes from human or rat brain. Neuropharmacology 24:751–759PubMedCrossRefGoogle Scholar
  34. Skolnick P, Paul SM (1982) Benzodiazepine receptors in the central nervous system. Int Rev Neurobiol 23:103–140PubMedCrossRefGoogle Scholar
  35. Tallman JF, Paul SM, Skolnick P, Gallager DW (1980) Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science 207:274–281PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • R. M. Arendt
    • 1
    • 2
  • D. J. Greenblatt
    • 1
  • D. C. Liebisch
    • 2
  • M. D. Luu
    • 3
  • S. M. Paul
    • 3
  1. 1.Division of Clinical PharmacologyTufts-New England Medical CenterBostonUSA
  2. 2.Department of NeuropharmacologyMax Planck Institute of PsychiatryMunichGermany
  3. 3.Clinical Neuroscience BranchNational Institute of Mental HealthWashingtonUSA

Personalised recommendations